Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst A. Berens now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback